Clinical Trial Analysis of Different Stages of HBV Patients Treated with Human CIK Cells

Fangfang Xia, Ruihua Song, Jingjing Zhang, Yang Zhu, Yao Yang, Ling He, Yun Cao, Chenlu Li, Zheng Wang, Shangli Cheng, Jian Ni, Lijun Ma, Ding Li, Daxiang Cui



Cellular immunotherapy has become a potential therapeutic method for different diseases. Herein, we reported clinical trial results of Cytokine-induced killer (CIK) cells used for patients with hepatitis B, cirrhosis and liver cancers from 2000 to 2015. Results showed CIK cell therapeutic effects were closely positively associated with CIK cell numbers, treated times and HBV genotypes. Different stages of HBV patients treated with > 1010 CIK cells per time for more than ten times exhibited remarkable decrease of HBV DNA numbers (P <0.01), Alt and Ast gradually recovered to normal scope, cytokine factors such as IFN-g, IL-1b, IL-2, IL-4, IL-6, IL-10, IL-22 and IL-27 exhibited obvious increase, lifespan of patients with cirrhosis and hepatocellular carcinoma were extended, and that all the patients felt better in sleep, diet and pain during the period of CIK therapy. In conclusion, CIK cell therapy is a good alternative therapeutic method and can be effectively used for treatment of different stages of HBV patients.

Full Text

Nano Biomedicine and Engineering.

Copyright © Shanghai Jiao Tong University Press